MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: filgrastim
Drug: dexamethasone
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-05-24

Last Posted Date: 2016-05-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 89

Registration Number: NCT00477971

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: cyclophosphamide
Drug: dexamethasone
Drug: lenalidomide

First Posted Date: 2007-05-24

Last Posted Date: 2011-08-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 53

Registration Number: NCT00478218

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-05-24

Last Posted Date: 2011-05-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT00478075

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: lenalidomide
Drug: melphalan
Drug: prednisone

First Posted Date: 2007-05-24

Last Posted Date: 2019-10-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 33

Registration Number: NCT00477750

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: rituximab
Drug: melphalan
Biological: Stem Cell
Biological: Sargramostim (GM-CSF)
Radiation: 90Y-Zevalin
Biological: 111In Zevalin

First Posted Date: 2007-05-24

Last Posted Date: 2018-05-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT00477815

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: RAD001
Drug: Sorafenib

First Posted Date: 2007-05-17

Last Posted Date: 2019-08-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 103

Registration Number: NCT00474929

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: MART-1 antigen
Biological: IL-2
Biological: gp100 antigen
Biological: GM-CSF
Biological: MART-1a peptide

First Posted Date: 2007-05-07

Last Posted Date: 2019-02-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT00470015

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Early Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: resiquimod

First Posted Date: 2007-05-07

Last Posted Date: 2014-10-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT00470379

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

Phase 3

Terminated

Conditions: Multiple Sclerosis
Fatigue

Interventions: Drug: Placebo
Drug: High Dose Aspirin (1300 mg/day)
Drug: Low Dose Aspirin (162 mg/day)

First Posted Date: 2007-04-30

Last Posted Date: 2014-05-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 62

Registration Number: NCT00467584

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States

Adapting Web-based Instruction to Baseline Knowledge of Physicians-in-training

Phase 2

Completed

Conditions: Medical Education
Medical Training
Internship and Residency

First Posted Date: 2007-04-27

Last Posted Date: 2010-01-15

Lead Sponsor: Mayo Clinic

Target Recruit Count: 144

Registration Number: NCT00466453

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy